ESC 365 - Dapagliflozin but not empagliflozin prevents atrial fibrillation in an experimental whole-heart model

ESC Professional Premium Access

Dapagliflozin but not empagliflozin prevents atrial fibrillation in an experimental whole-heart model

Session: Insights into arrhythmia mechanisms

Topic: Cellular Electrophysiology

Speaker: Professor G. Frommeyer (Munster, DE)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Gerrit Frommeyer

University Hospital of Munster, Munster (Germany)

0 follower

2 more presentations in this session

State-of-the-art lecture in arrhythmia mechanisms.

Speaker: Professor U. Schotten (Maastricht, NL)

Dapagliflozin exhibits class I antiarrhythmic effects which suppress action potential formation in human atrial cardiomyocytes

Speaker: Miss A. Paasche (Heidelberg, DE)

Access the full session

Insights into arrhythmia mechanisms

Speakers: Professor G. Frommeyer, Professor U. Schotten, Miss A. Paasche

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources